TNFRSF8 and Hodgkins lymphoma: In this context a CD30 antibody-drug conjugate, brentuximab vedotin (BV), has achieved therapeutic approval for peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and Hodgkin lymphoma, both as monotherapy or in combination with standard chemotherapy [126, 127].